Chester County News and Community Website
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, PA, is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a key player in the pharmaceutical industry, recently unveiled its financial results for the fourth quarter and full year of 2023, which …
Galera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challenges Read More MALVERN, PA — Galera Therapeutics, Inc. (NASDAQ: GRTX) this week unveiled its financial results for the third quarter of 2023, alongside a series of significant corporate updates that signal a …
Galera Therapeutics Reports Q3 2023 Financial Results Amid Strategic Shift Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug …
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) recently announced that a Type A Meeting has been scheduled for September 28, 2023, with the U.S. Food and Drug Administration (FDA) …
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the …
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, this week announced financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.
Galera Therapeutics Announces Q2 Financial Results and Advancements in FDA Discussions and Anti-Cancer Research Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that it recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New …
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, this week presented data from the Phase 3 ROMAN trial demonstrating avasopasem manganese (avasopasem) improved preservation of kidney …
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Galera’s second product candidate, rucosopasem manganese (rucosopasem), …
Galera’s Second Candidate Granted Orphan Drug Designation for Pancreatic Cancer Treatment Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023, and provided recent corporate updates.
Galera Reports First Quarter 2023 Financial Results, Recent Corporate Updates Read More